Federal Oversight Group Has Complaints But Says Yes To CRISPR Trial
By Alex Lash,
Xconomy
| 06. 21. 2016
Despite worries about conflict of interest, a National Institutes of Health committee that oversees the use of gene therapy and other cutting edge biomedical technologies voted today to let researchers move ahead with a landmark clinical trial. Depending on timing, it could be the first to use the gene editing system CRISPR-Cas9 in a human treatment.
There are still hurdles. The University of Pennsylvania School of Medicine team, led by high profile cancer researcher Carl June and funded by billionaire Sean Parker’s new cancer institute, must get a green light from the FDA, according to NIH regulations. It’s not clear when Penn hopes to start a trial, which would be small and designed to evaluate the safety of an experimental treatment for several types of cancer.
[Updated with Penn Medicine statement.] In response to questions about the conflict of interest and a timeline for the trial, a spokeswoman emailed a statement that said Penn Medicine “was pleased” by the vote and looks forward to presenting the trial for FDA review. It did not address the conflict or...
Related Articles
By Katherine Long, Ben Foldy, and Lingling Wei, The Wall Street Journal | 12.13.2025
Inside a closed Los Angeles courtroom, something wasn’t right.
Clerks working for family court Judge Amy Pellman were reviewing routine surrogacy petitions when they spotted an unusual pattern: the same name, again and again.
A Chinese billionaire was seeking parental...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Sarah Kliff, The New York Times | 12.10.2025
Micah Nerio had known since his early 30s that he wanted to be a father, even if he did not have a partner. He spent a decade saving up to pursue surrogacy, an expensive process where he would create embryos...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
